Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The study will include patients with diagnosed cancer, diagnosed and qualified for further systemic treatment at the National Institute of Oncology in Warsaw. Patients must give informed and voluntary consent to participate in the study and meet all the conditions for inclusion in the study Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2. 2. Age ≥18 years at the time of signing the informed consent. 3. Known neoplastic disease prior to the initiation of chemotherapy with a high dose of anthracyclines (doxorubicin ≥ 240 mg / m2 b.w. or epirubicin ≥ 540 mg / m2 b.w.) 4. No history of heart failure (left ventricular ejection fraction ≥ 50% as assessed by echocardiography). 5. Women of child-bearing age must have a negative serum or urine pregnancy test. 6. All males and females must consent to the use of effective contraception throughout the study period and after study medication is discontinued. 7. Sexually active women of childbearing potential must use 2 effective methods of contraception (abstinence, IUD, oral contraceptive or double barrier device) from informed consent and for at least 6 months after study drug discontinuation 8. Sexually active men and their sexual partners must use effective methods of contraception from the moment they sign their informed consent to participate in the study and for at least 3 months after discontinuation of the study drug. Exclusion Criteria: 1. History of heart failure 2. Left ventricle systolic dysfunction assessed by echocardiography (LVEF \<50%) 3. Significant valve disease 4. Previous chemotherapy or radiation to the chest 5. Symptomatic hypotension and / or SBP \<100 mmHg at Visit 1 or Visit 2 6. Liver disease, as determined by ALT, AST, or alkaline phosphatase levels above 3 x upper limit of normal (ULN) at visit 1. 7. Renal impairment, defined as eGFR \<20 mL / min / 1.73 m2 or dialysis requirement, as determined at Visit 1. 8. History of ketoacidosis 9. Gastrointestinal surgery or gastrointestinal disturbance that could impair drug absorption 10. Presence of any disease with a life expectancy \<1 year in the opinion of the investigator. 11. Treatment with any SGLT-2 inhibitor for up to 3 months prior to study enrollment. 12. Pregnancy or breastfeeding 13. Drug or alcohol abuse 14. Suspected non-compliance and irregular use of study drug 15. Inability to perform CMR, e.g. claustrophobia, weight\> 120 kg, etc.